UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102, which is in Phase III clinical trials for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-301 for the treatment of high-grade non-muscle invasive bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins; Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and strategic research collaboration with MD Anderson to advance investigational treatment for high-grade bladder cancer. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
Revenue of UroGen Pharma Ltd. (URGN)
Revenue in 2023 (TTM): $82.71 M
According to UroGen Pharma Ltd.'s latest financial reports the company's current revenue (TTM) is $82.71 M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history of UroGen Pharma Ltd.
Annual Revenue
| Year | Revenue | Gross Profit | Ebitda | Income Before Tax | Net Income |
|---|---|---|---|---|---|
| 2023 | $82.71 M | $73.35 M | $-63,831,000 | $-98,324,000 | $-102,244,000 |
| 2022 | $64.36 M | $56.7 M | $-78,031,000 | $-108,028,000 | $-109,163,000 |
| 2021 | $48.04 M | $42.89 M | $-90,154,000 | $-109,371,000 | $-110,820,000 |
| 2020 | $11.8 M | $10.79 M | $-122,709,000 | $-125,110,000 | $-128,484,000 |
| 2019 | $18 K | $18 K | $-108,154,000 | $-105,146,000 | $-100,530,000 |
| 2018 | $1.13 M | $-675,000 | $-77,180,000 | $-75,532,000 | $-75,657,000 |
| 2017 | $8.16 M | $7.56 M | $-19,743,000 | $-19,981,000 | $-20,000,000 |
| 2016 | $17.53 M | $17.5 M | $1.01 M | $-1,941,000 | $-1,941,000 |
| 2015 | $ | $-113,000 | $-12,297,000 | $-12,689,000 | $-12,689,000 |
| 2014 | $ | $ | $-4,339,000 | $-4,476,000 | $-4,557,000 |
| 2013 | $ | $ | $-3,371,000 | $-3,306,000 | $-3,306,000 |